+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Capricor Therapeutics - logo

Capricor Therapeutics focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.

From
From
From
Global Cell Therapy Market 2023-2027 - Product Thumbnail Image

Global Cell Therapy Market 2023-2027

  • Report
  • August 2023
  • 159 Pages
  • Global
From
Duchenne Muscular Dystrophy - Pipeline Review, H2 2020 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 413 Pages
  • Global
From
Exosome Research Global Market Report 2024 - Product Thumbnail Image

Exosome Research Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Technology Growth Opportunities for Exosome-Mediated Drug Delivery - Product Thumbnail Image

Technology Growth Opportunities for Exosome-Mediated Drug Delivery

  • Report
  • September 2022
  • 62 Pages
  • Global
From
Ischemic Cardiomyopathy - Pipeline Insight, 2024 - Product Thumbnail Image

Ischemic Cardiomyopathy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Exosome Diagnostics and Therapeutics: Global Markets 2021-2026 - Product Thumbnail Image

Exosome Diagnostics and Therapeutics: Global Markets 2021-2026

  • Report
  • November 2021
  • 255 Pages
  • Global
From
Left Ventricular Dysfunction - Pipeline Insight, 2024 - Product Thumbnail Image

Left Ventricular Dysfunction - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Loading Indicator